Patrick Daly

DocwireNews

Using data from the SEAM-RA (Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Rheumatoid Arthritis) trial, investigators examined changes in patient-reported outcomes (PROs) after treatment withdrawal in rheumatoid arthritis that subsequently worsened cases in patients who had achieved remission.Published in the Journal of Clinical Rheumatology, the analysis stated PROs were more durable in patients who transitioned from etanercept and methotrexate combination therapy to etanercept monotherapy compared with those who transitioned to methotrexate monotherapy.<h3>Study Characterizes Treatment Withdrawal in Rheumatoid Arthritis</h3>Participants in the SEAM-RA trial completed the following assessments for 48 weeks after treatment withdrawal in rheumatoid arthritis after remission:<ul>
<li>Physician&rsquo;s Global Assessment of Disease Activity (PtGA)</li>
<li>Patient&rsquo;s Assessment of Joint PainA</li>
<li>Health Assessment Questionnaire-Disability Index</li>
<li>36-Item Short-Form Health Survey</li>
</ul>Among 253 patients, 121 had disease worsening per clinician&rsquo;s SDAI assessment, while 132 did not. Authors noted the overall study population had PRO declines over the course of the study; however, patients on <a href="https://medlineplus.gov/druginfo/meds/a602013.html" target="_blank" rel="noopener">etanercept</a> monotherapy had lesser declines in PtGA and Patient&rsquo;s Assessment of Joint Paint scores compared with those on methotrexate monotherapy.The authors also noted Simple Disease Activity Index (SDAI) and PROs agreed, as more patients with disease worsening had PRO declines above a minimal clinically important difference for all scores versus patients without worsening. Generally, the authors concluded &ldquo;patients who received rescue therapy following disease worsening might be able to regain their outcomes but to a lesser extent than those remaining in remission.&rdquo;Interestingly, &ldquo;patient-reported outcome deterioration tended to occur before SDAI disease worsen,&rdquo; the authors ended, &ldquo;suggesting that patients may recognize disease worsening sooner than a clinician would using the SDAI.&rdquo;Read More Related Research at <a href="https://www.docwirenews.com/rheumatoid-arthritis-resource-center/">the Rheumatoid Arthritis Resource Center</a>

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

Etanercept Superior After Treatment Withdrawal in Rheumatoid Arthritis

Rheumatoid Arthritis

Using data from the SEAM-RA (Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Rheumatoid Arthritis) trial, investigators examined changes ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe